May 2018

New non-invasive biomarker for diagnosis and prognosis in male sterility

Leave a Comment / Genes, Disease and Therapy Program, Human Molecular Genetics, Traslacional Medicine / By

Researchers from the Human Molecular Genetics group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, have identified a new non-invasive biomarker of the presence of sperm in the testis of azoospermic men, who represent 10% of the cases of male sterility. The work, published in the prestigious international journal Human Reproduction, […]

New non-invasive biomarker for diagnosis and prognosis in male sterility Read More »

Green light to REMAB, a new IDIBELL Spin-Off

Innate Immunity and Pathology of the Critical patient, Innovation, Traslacional Medicine / By

REMAB Therapeutics, the new IDIBELL Spin-off, was officially launched by the end of April 2018. The company has doctors Rafael Mañez (IP) and Daniel Bello, from the research group on innate immunity and pathology of the critical patient, as founding partners, together with IDIBELL. REMAB’s main objective is the development of a new molecule for

Green light to REMAB, a new IDIBELL Spin-Off Read More »

IDIBELL hosts the ”Marie Sklodowska-Curie Individual Actions, 2018 call” Information Day

Leave a Comment / Uncategorised / By

On May 10th, the “Marie Skłodowska-Curie Individual actions, 2018 call” infoday was held in the facilities of Duran i Reynals Hospital. The session, which was co-organized by the Bellvitge Biomedical Research of Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Agency for the Management of University and Research Grants (AGAUR), filled the auditorium

IDIBELL hosts the ”Marie Sklodowska-Curie Individual Actions, 2018 call” Information Day Read More »

A new drug shows preclinical efficacy in Rett syndrome

Leave a Comment / Cancer, Cancer Epigenetics / By

A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models. The study, led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and

A new drug shows preclinical efficacy in Rett syndrome Read More »

New collaboration agreement between IDIBELL and IMLCFC

Leave a Comment / Uncategorised / By

The Bellvitge Biomedical Research Institute (IDIBELL) has recently signed a collaboration agreement with the Institute of Legal Medicine and Forensic Sciences of Catalonia (IMLCFC). The main objective of this agreement is to establish a collaboration between both institutions to jointly develop programs and activities linked to biomedical research, as well as to achieve significant improvements

New collaboration agreement between IDIBELL and IMLCFC Read More »

How does BRCA1 breast cancer become resistant to chemotherapy?

Leave a Comment / Breast cancer, Cancer, Hereditary cancer , Tumor and stromal chemoresistance  / By

Researchers of the proCURE program of the Catalan Institute of Oncology, Oncobell-IDIBELL, have recently published a scientific paper in which they describe the genetic mechanisms by which a breast tumor associated to a mutated BRCA1 gene becomes resistant to chemotherapy.   Breast cancers that appear in women with BRCA1 mutations usually present a poor prognosis

How does BRCA1 breast cancer become resistant to chemotherapy? Read More »

Scroll to Top